Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Other research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Raymond James increased their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Finally, Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ ALNY traded up $0.39 on Thursday, hitting $253.74. The company had a trading volume of 718,060 shares, compared to its average volume of 877,936. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The business has a 50 day moving average of $271.93 and a two-hundred day moving average of $240.19. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a market capitalization of $32.73 billion, a P/E ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,370 shares of company stock worth $2,100,703. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Diversified Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $1,210,000. Los Angeles Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares during the period. Breakwater Capital Group acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $249,000. Sanctuary Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $578,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 22.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after acquiring an additional 13,422 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.